Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shanghai Biolaxy Given SFDA OK for Oral Insulin IND

publication date: Nov 25, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Biolaxy received an SFDA approval of an investigational new drug application (IND) for its oral insulin product, Nodlin. Nodlin uses a patented bio-adhesive nano-particle oral delivery technology (NOD) to transport insulin through the stomach to the blood stream. No orally administered insulin drugs are approved currently. With a successful IND, Shanghai Biolaxy can begin clinical trials of the product. More details...

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners